Rubius Therapeutics, Inc. (RUBY) Stock Analysis
DELISTED 2023
What happened to Rubius Therapeutics, Inc. (RUBY) stock?
Rubius Therapeutics, Inc. (RUBY) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- December 2023
- Last recorded price (historical):
- $0.057 (last quote on record before the December 2023 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Rubius Therapeutics, Inc. (RUBY). Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing red cell therapeutics (RCTs) for severe diseases. Their pipeline includes RCTs targeting solid tumors, HPV-positive tumors, and type 1 diabetes.
Last analyzed: May 10, 2026Rubius Therapeutics, Inc. (RUBY) Healthcare & Pipeline Overview
More about this archive record
Can I still buy RUBY shares?
No. RUBY stopped trading on public markets in December 2023, so the shares are not available through a broker. Anything you see quoted for RUBY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RUBY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Rubius Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.